AT
Attovia TherapeuticsAttovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
8 Pulse stories
S
SanofiSanofi is a global biopharmaceutical company developing and manufacturing medicines and vaccines across specialty care, immunology, oncology, and rare diseases.
2 Pulse stories
Total Raised
~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)
Attovia TherapeuticsSanofi
Last Valuation
$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)
Attovia TherapeuticsSanofi
Biotech
Sector
Biotech
2023
Founded
1973
San Carlos, CA
HQ
Paris, France
Public (ATTO)
Status
Public (SNY)
Attovia Therapeutics investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Sanofi investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Attovia Therapeutics and Sanofi.